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otavirus  VP6  protein  expressed  in cell  culture  by  HSV-1-based
ectors
xpresión  en  cultivo  celular  de  la  proteína  VP6  de  rotavirus  mediante  el  uso
e  vectores  virales  basados  en  HSV-1
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erpes  simplex  virus  (HSV)-based  vectors  have  been  used  as
latforms  for  the  generation  of  genetic  vaccines  against  dif-
erent  viruses.  Some  of  the  advantages  of  defective  HSV-1
ectors  include:  (a)  HSV-1  can  infect  most  cell  types,  includ-
ng  antigen-presenting  cells;  (b)  HSV-1  vectors  have  a  large
ransgene  capacity  (up  to  150-kbp);  (c)  HSV-1  vectors  can  be
esigned  to  cause  no  toxicity;  (d)  different  studies  showed
hat  mice  vaccinated  with  such  vectors  encoding  antigens
rom  different  pathogens  were  partially  protected1,3,  indi-
ating  that  HSV-1  based  vectors  are  attractive  tools  for  the
evelopment  of  safe  genetic  vaccines.
There  are  two  main  platforms  of  HSV-1-derived  vectors:
efective  recombinant  viruses  (deleted  in  ICP4,  ICP27  and
CP22  genes)  and  amplicons.  Defective  HSV-1  viruses  can
nly  be  propagated  using  a  complementing  cell  line.  Pro-
uction  of  amplicons  depends  on  helper  functions,  provided
n  trans. In  both  systems,  different  genetic  elements  were
ntentionally  introduced  to  conduct  the  heterologous  gene
xpression  and  to  allow  the  titration  of  the  vector  stocks  in
ifferent  cell  lines2,4.
In  our  group,  HSV-1  vectors  were  developed  for  the
xpression  of  several  rotavirus  genes.  Genes  from  other
athogens  were  also  expressed,  thus  generating  a  set  of∗ Corresponding author.
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erent  diseases.
In  this  section,  we  show  two  different  HSV-1  vectors  that
xpress  the  VP6  protein  from  different  rotavirus  strains.
igure  1  shows  a  defective  recombinant  virus  expressing
imultaneously  Enhanced  Green  Fluorescent  Protein  (EGFP)
nd  VP6  from  murine  rotavirus  strain  EC,  in  Figure  2  and
ovie  S1,  an  amplicon  vector  overexpressing  VP6  from  a
a  strain  of  human  rotavirus  is  shown.  In  both  cases,  the
P6  proteins  were  recognized  by  a  monoclonal  antibody
nd  were  found  extensively  expressed  forming  ﬁlaments
long  the  cells,  showing  a  typical  intra-cellular  pattern,  in
he  absence  of  other  rotavirus  protein.  These  results  show
hat  the  recombinant  proteins  maintain  the  speciﬁc  capac-
ty  of  self-assembly  of  the  native  protein  and,  therefore,
re  potential  vaccine  candidates  to  be  explored.  Recently,
esults  obtained  by  our  group  and  in  collaboration  with  oth-
rs,  have  demonstrated  the  feasibility  of  these  systems  to
nduce  protective  immune  responses  against  different  viral
nfections1,3.
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Rotavirus  VP6  protein  expressed  in  cell  culture  by  HSV-1-based  v
Figure  1  MDBK  cells  were  transduced  with  T0EC-VP6  recom-
binant  vector.  Permeabilized  cells  were  probed  with  monoclonal
antibody  (MAb)  2F,  directed  against  the  UK  strain  rotavirus
VP6, followed  by  Alexa-594  anti-mouse  antibody  (Molecular
Probes,  USA).  Nuclear  DNA  was  stained  with  4′,6,-Diamidino-
2-Phenylindole,  Invitrogen  (DAPI).  Wa-VP6  and  EGFP  expression
were observed  under  the  microscope  and  the  obtained  images
were merged  into  the  same  picture.  Bar,  20  m.
Figure  2  Vero  cells  were  transduced  with  HSV  [Wa-VP6]
amplicon  vector.  Permeabilized  cells  were  probed  with  MAb
2F, followed  by  Alexa-594  anti-mouse  antibody  (Molecular
Probes,  USA).  Nuclear  DNA  was  stained  with  4′,6,-Diamidino-
2-Phenylindole,  Invitrogen  (DAPI).  Wa-VP6  and  EGFP  expression
were observed  under  the  microscope,  and  the  obtained  images
were  merged  into  the  same  picture.  The  bar  indicates  20  m.
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